GOS-HMO Nutritional Composition for Microbiota-Driven GABA Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for nutritional solutions that can naturally increase the synthesis of gamma-aminobutyric acid (GABA) by the microbiota of infants and children to treat or prevent stress and mood disorders, as pharmaceutical interventions may have adverse effects on neuronal development.
Innovation Solution
A combination of galacto-oligosaccharides (GOS) and a specific mixture of human milk oligosaccharides (HMOs), comprising 2′-fucosyllactose (2′FL) and difucosyllactose (DFL) or lacto-N-tetraose (LNT) and 6′ sialyllactose (6′SL), is used to enhance GABA biosynthesis by the gut microbiota.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pharmaceutical interventions are used to treat stress and mood disorders in infants and children, then therapeutic effectiveness is improved, but adverse effects on neuronal development occur
Solution Approach 1:
The patent introduces gut microbiota as an intermediary system that converts dietary oligosaccharides (GOS and HMOs) into GABA, which then acts on the brain to reduce stress. This indirect pathway avoids direct pharmaceutical intervention while achieving therapeutic effects, thus resolving the contradiction between effectiveness and safety.
Solution Approach 2:
The patent replaces the pharmaceutical (chemical) system with a nutritional system based on oligosaccharides that work through microbial fermentation to produce GABA. This substitution eliminates the harmful side effects of pharmaceuticals while maintaining therapeutic benefits through a natural biochemical pathway.
2Object-affected harmful factors
If nutritional solutions are used to increase GABA synthesis by microbiota, then safety is improved, but effectiveness in treating stress is insufficient
Solution Approach 1:
The patent combines multiple oligosaccharides (GOS and specific HMOs like 2′-fucosyllactose, difucosyllactose, lacto-N-tetraose, and 6′ sialyllactose) to create a synergistic nutritional formulation. This composite approach enhances GABA production by the microbiota more effectively than single components, thereby improving therapeutic effectiveness while maintaining safety.
Solution Approach 2:
The patent specifies precise compositional parameters (types and amounts of oligosaccharides) to optimize GABA synthesis. By controlling these parameters, the formulation achieves sufficient GABA production to effectively treat stress and mood disorders while maintaining safety profiles.
3Productivity
If specific combinations of GOS and HMOs are used, then GABA biosynthesis is increased, but formulation complexity increases
Solution Approach 1:
The patent divides the complex mixture of HMOs into specific identifiable components (2′-fucosyllactose, difucosyllactose, lacto-N-tetraose, 6′ sialyllactose), each contributing to GABA production. This segmentation allows for targeted formulation and easier manufacturing while maintaining high GABA biosynthesis efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination effectively increases GABA production by the gut microbiota, restoring the functionality of the gut-brain axis to healthy levels, thereby alleviating stress and mood disorders in infants and children.
Implementation Method 1
the combination showed increased biosynthesis of gamma-aminobutyric acid (GABA) by the gut microbiota
Data Source
AI summary
The present invention relates to a combination of galacto-oligosaccharides (GOS) and a mixture of human milk oligosaccharides (HMOs), or nutritional compositions comprising the combination. The combination or compositions are for use in treating and/or preventing stress and/or a mood disorder in an infant, young child and/or child. The mixture of HMOs consists or consists essentially of 2′-fucosyllactose (2′FL) and difucosyllactose (DFL) or of lacto-N-tetraose (LNT) and 6′ sialyllactose (6′SL). The present invention also relates to the use of a combination of galacto-oligosaccharides (GOS) and a mixture of human milk oligosaccharides (HMOs), or compositions comprising the combination, for treating and/or preventing stress and/or a mood disorder in an infant, young child and/or child, wherein the mixture of HMOs consists or consists essentially of 2′-fucosyllactose (2′FL) and difucosyllactose (DFL) or of lacto-N-tetraose (LNT) and 6′ sialyllactose (6′SL).